

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human ST8 α -2,8-Sialyltransferase 8A/ST8SIA1 in direct ELISAs and Western blots.
Source	Polyclonal Sheep IgG
Purification	Antigen Affinity-purified
Immunogen	Chinese hamster ovary cell line CHO-derived recombinant human ST8 α -2,8-Sialyltransferase 8A/ST8SIA1 Tyr49-Ser356 Accession # Q92185
Conjugate	Alexa Fluor 488 Excitation Wavelength: 488 nm Emission Wavelength: 515-545 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

Western Blot	Optimal dilution of this antibody should be experimentally determined.
Immunohistochemistry	Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Gangliosides are acidic glycosphingolipids that contain one or more sialic acid residues and are particularly prevalent on neuronal cells (1). Ganglioside GD3 is involved in cell adhesion and the growth of cultured malignant cells (2). ST8SIA1 is a sialyltransferase that catalyzes the transfer of sialic acid from CMP-sialic acid to GM3 (NeuNAc α 2-3Gal β 1-4Glc-Cer) to produce GD3 (NeuNAc α 2-8NeuNAc α 2-3Gal β 1-4Glc-Cer) and GT3 (NeuNAc α 2-8NeuNAc α 2-8NeuNAc α 2-3Gal β 1-4Glc-Cer) in a successive manner (3); therefore the enzyme has both GD3 and GT3 synthase activity (4). ST8SIA1 is mainly expressed in adult and fetal brain, and its expression is enhanced in melanoma cell lines (3, 4, 5). Like most known glycosyltransferases, ST8SIA1 is predicted as a type II transmembrane protein with a short N-terminal cytoplasmic domain and a single-pass transmembrane domain followed by an enzymatic domain in the lumen of the Golgi apparatus. However, recently GD3 synthase activity was demonstrated at the surface of epithelial and melanoma cells, suggesting glycosphingolipid synthesis may occur at the cell membrane (6). Recombinant ST8SIA1 also showed activity on fetuin from fetal calf serum, when measured using a phosphatase-coupled method (7).

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.